

Summary of risk management plan for Iressent 100 mg harde capsule met gereguleerde afgifte  
(Nitrofurantoin)

This is a summary of the risk management plan (RMP) for Iressent 100 mg harde capsule met gereguleerde afgifte. The RMP details important risks of Iressent 100 mg harde capsule met gereguleerde afgifte, how these risks can be minimised, and how more information will be obtained about Iressent 100 mg harde capsule met gereguleerde afgifte's risks and uncertainties (missing information).

Iressent 100 mg harde capsule met gereguleerde afgifte's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Iressent 100 mg harde capsule met gereguleerde afgifte should be used.

Important new concerns or changes to the current ones will be included in updates of Iressent 100 mg harde capsule met gereguleerde afgifte's RMP.

### **I. The medicine and what it is used for**

Iressent 100 mg harde capsule met gereguleerde afgifte is authorised for use in adults and children over 12 years old for treatment of acute uncomplicated lower urinary tract infections caused by nitrofurantoin sensitive microorganisms.

It contains nitrofurantoin as the active substance, and it is given orally.

### **II.Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Iressent 100 mg harde capsule met gereguleerde afgifte, together with measures to minimise such risks and the proposed studies for learning more about Iressent 100 mg harde capsule met gereguleerde afgifte's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals.
- Important advice on the medicine's packaging.
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly.
- The medicine's legal status - the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

#### **II.A List of important risks and missing information**

Important risks of Iressent 100 mg harde capsule met gereguleerde afgifte are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are

concerns for which there is sufficient proof of a link with the use of Iressent 100 mg harde capsule met gereguleerde afgifte. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

### ***II.B Summary of important risks***

The safety information in the proposed Product Information is aligned to the reference medicinal product.

### ***II.C Post-authorisation development plan***

#### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of Iressent 100 mg harde capsule met gereguleerde afgifte.

#### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for Iressent 100 mg harde capsule met gereguleerde afgifte.